Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 102 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Newly Diagnosed Breast Cancer Clear all
Terminated Phase 1 Interventional

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

NCT04060342
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma
Interventions
GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
Drug
Lead sponsor
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 9, 2026, 10:45 PM EDT
Withdrawn Phase 2 Interventional

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

NCT03065712
View directory record Official record
Conditions
Breast Cancer
Interventions
F-18 Fluoroestradiol, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 9, 2026, 10:45 PM EDT
Terminated Phase 1 Interventional

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

NCT00754312
View directory record Official record
Conditions
Breast Cancer
Interventions
SNDX-275
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Phase 2 Interventional

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

NCT00410657
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study
Biological · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Not applicable Interventional

Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.

NCT03027063
View directory record Official record
Conditions
Breast Cancer Female, Adriamycin Toxicity
Interventions
10,000 steps, Usual Care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 9, 2026, 10:45 PM EDT
Completed No phase listed Observational

Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105

NCT00959244
View directory record Official record
Conditions
Breast Cancer
Interventions
high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

NCT01216176
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, AZD0530 (saracatinib), Placebo
Drug
Lead sponsor
Joyce Marie Slingerland, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

cMet CAR RNA T Cells Targeting Breast Cancer

NCT01837602
View directory record Official record
Conditions
Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions
cMet RNA CAR T cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 9, 2026, 10:45 PM EDT
Terminated No phase listed Observational

Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT

NCT01144754
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Rituximab
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00010023
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, cisplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer

NCT00046891
View directory record Official record
Conditions
Breast Cancer, Neurotoxicity
Interventions
Ginkgo Biloba, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
175
States / cities
Scottsdale, Arizona • Lompoc, California • Santa Barbara, California + 111 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

NCT01928186
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis, Run-in (short pre-surgery course) of endocrine-targeted therapy
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 9, 2026, 10:45 PM EDT
Terminated Phase 1Phase 2 Interventional

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

NCT00216047
View directory record Official record
Conditions
Breast Cancer
Interventions
PTK787, Trastuzumab
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients

NCT04106609
View directory record Official record
Conditions
Breast Cancer
Interventions
Supervised, individualized exercise oncology program, Current standard of care
Other
Lead sponsor
Karen Wonders
Other
Eligibility
30 Years to 80 Years · Female only
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 9, 2026, 10:45 PM EDT
Not listed Not applicable Interventional

Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients

NCT02488187
View directory record Official record
Conditions
Breast Cancer
Interventions
ABUS
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT01847001
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions
Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
Drug · Other · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 9, 2026, 10:45 PM EDT
Active, not recruiting Not applicable Interventional

YES Study - Newly Diagnosed/Metastatic Intervention

NCT04379414
View directory record Official record
Conditions
Breast Cancer, Symptom, Behavioral
Interventions
YES portal
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

NCT02520063
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Everolimus, TRC105
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Not applicable Interventional

Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer

NCT03176979
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Contrast Agent, Digital Tomosynthesis Mammography, Dual-Energy Contrast-Enhanced Digital Spectral Mammography
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Digital Breast Tomosynthesis + Standard 2- Dimensional Mammography in Breast Cancer

NCT03190083
View directory record Official record
Conditions
Breast Cancer
Interventions
2-dimensional mammogram, digital breast tomosynthesis (DBT)
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 9, 2026, 10:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

NCT02883062
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Atezolizumab, Biospecimen Collection, Carboplatin, Lumpectomy, Mastectomy, Paclitaxel
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 9, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer

NCT00005886
View directory record Official record
Conditions
Breast Cancer
Interventions
arzoxifene hydrochloride, tamoxifen citrate
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 9, 2026, 10:45 PM EDT
Terminated Early Phase 1 Interventional

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

NCT00499733
View directory record Official record
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 9, 2026, 10:45 PM EDT